Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2037106 | 0.84 | DAO (0.37) | MAPTLMNAMEN1KMT2AATM | |
| SCHEMBL17925583 | 0.79 | MAPT (0.36) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL9316683 | 0.78 | LMNA (0.36) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL1269548 | 0.74 | F10 (0.44) | MAPTLMNAKDM4EKMT2AF2 | |
| SCHEMBL2040186 | 0.74 | KDM4E (0.42) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL20475329 | 0.74 | MAPT (0.41) | MAPTLMNAKDM4EF2F10 | |
| SCHEMBL19860132 | 0.73 | ALDH1A1 (0.39) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL9294262 | 0.73 | F2 (0.50) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL15548874 | 0.73 | MAPT (0.40) | MAPTLMNAKDM4EMEN1KMT2A | |
| SCHEMBL21609309 | 0.72 | F10 (0.43) | MAPTLMNAKDM4EF2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| CN-118165002-A | Polycyclic compounds and methods of use thereof | 桑诺维恩药品公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3252057-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | PSYCHOGENICS INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710245-B2 | Multicyclic compounds and methods of use thereof | PSYCHOGENICS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
| EP-2507245-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | MAPT 234/4885LMNA 1175/4885KDM4E 4068/4885 |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | MAPT 234/4885LMNA 1175/4885KDM4E 4068/4885 |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | MAPT 234/4885LMNA 1175/4885KDM4E 4068/4885 |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | GRIN2C, NLN, COMT | MAPT 234/4885LMNA 1175/4885KDM4E 4068/4885 |
| US-20140256712-A1 | Multicyclic Compounds and Methods of Use Thereof | GRIN2C, NLN, COMT | MAPT 234/4885LMNA 1175/4885KDM4E 4068/4885 |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | MAPT 234/4885LMNA 1175/4885KDM4E 4068/4885 |
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SLC6A3, SLC6A11, SLC6A13 | MAPT 156/4885LMNA 2475/4885KDM4E 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.